Tag

Lightox Archives - Walton Marketing

LightOx welcome Rebecca Crow as Head of Projects

By | Client PR Stories | No Comments

LightOx Ltd, a company developing novel therapeutic treatments including light activated chemotherapy for early-stage oral cancer, has appointed Rebecca Crow as Head of Projects. The new appointment takes the life sciences business to a team of 11 as they move into larger offices at their city centre base in Newcastle. Rebecca’s appointment supports their goal of bringing their revolutionary mouth cancer treatment to market. Joining in January 2024 as Head of Projects and following a wave of new investment, project launches and grant funding, Rebecca will be responsible for helping the business deliver on a number of their targets. Working with key partners, the appointment aims to prepare the business for the launch of clinical trials for the lead candidate LXD191 to treat mouth cancer. Dr Sam Whitehouse, Chief Executive Officer at LightOx said; “I am delighted to welcome Rebecca to the team. She brings with her a real wealth of experience with former roles in the Newcastle Gateshead investment team and at the Newcastle NHS Trust where she was responsible for managing a number of trials. Her knowledge will be invaluable in helping us navigate our own way towards clinic and we have every confidence that Rebecca will play…

Read More

Life science pioneers secure £2.5m in grants

By | Client PR Stories | No Comments

Newcastle based Life Sciences and Biomedical businesses, LightOx, NunaBio, Magnitude Biosciences and Hexis Lab are celebrating securing several grant awards amounting to over £2.5million from Innovate UK’s latest round of R&D grants. Innovate UK provides the UK’s most innovative companies grant funding to help accelerate their growth and leverage private sector investment in the region. Through the support of advocates such as Labour’s Shadow Science MP Chi Onwurah, the region is able to demonstrate its capability and excellence in commercialising scientific breakthroughs. The funding will be used to advance the pharmaceutical and biotechnology research services, technology and drug development of these stand out companies. Innovate UK, part of UK Research and Innovation, have invested up to £25 million in a range of projects across the country this year. Supporting UK businesses to develop solutions that address significant health or healthcare challenges. From cancer prevention, development of new DNA based drug products, testing regimes and tailored treatments, the group are collectively transforming the delivery of healthcare and the development of new health technologies. The North East is fast becoming a hot bed of talent and innovation, with a notable rise in Life Sciences and Biomedical companies in the region proud to…

Read More

LightOx win £1.1 million Biomedical Catalyst grant to develop oral cancer drug

By | Client PR Stories | No Comments

Newcastle based LightOx announces today that it has been awarded a £1.1m project grant from Innovate UK, for the development of its light activated drug LXD191 to treat oral cancer patients. LightOx will work with the clinical team at the Liverpool Head and Neck Centre, University of Liverpool – Molecular and Clinical Cancer Medicine, and Liverpool University Hospitals NHS Foundation Trust. Working with the Liverpool team LightOx will finalise the drug formulation and clinical trial plans in order to then bring the drug to patients. The company was awarded the grant to formulate and manufacture their leading drug compound LXD191 to be used to treat oral cancer patients and pre-cancerous lesions that are detected in clinic. The LightOx team will work closely with partners to deliver a “chair-side” treatment for patients suffering from early-stage cancers. The drug which is currently the first of its kind to be developed for oral cancer is applied topically to the cancerous cells and is activated using a specific light source to kill the cancerous cells in the mouth. The treatment provides a minimally invasive alternative to surgery which currently remains the only other available option for patients, and often results in a reduced quality…

Read More